Strategic Partnerships AffaMed has a history of strategic licensing and collaboration with ophthalmology and neurology-focused partners across Greater China, South Korea, ASEAN regions, and globally. This indicates a strong willingness to co-develop and commercialize products, suggesting sales opportunities through co-promotion, joint ventures, or license-in discussions with regional distributors and larger pharma players.

Ophthalmic Focus The company actively develops ophthalmic products such as DEXTENZA and EVOLUX IOL, signaling a core market in eye care. This presents sales opportunities with ophthalmology clinics, hospital systems, and partner distributors in ASEAN and Greater China, particularly for device-based and sustained-release formulations.

Neurology Expansion AffaMed collaborates on digital therapies (DTx) for neurological disorders and PSCI, backed by partnerships with Beijing Tiantan Hospital and IBT. This opens avenues for selling digital health platforms, remote monitoring solutions, and integration services to hospitals, academic centers, and payer programs in China and neighboring markets.

Clinical Stage Advantage As a clinical-stage company with ongoing development across pharma, digital, and surgical products and substantial funding, AffaMed may seek strategic investors, CRO partnerships, and contract manufacturing arrangements. This creates opportunities for services, milestones-driven collaborations, and capacity-based conversations with contract manufacturing and clinical development partners.

Regional Focus, Global Reach With a focus on Greater China and ASEAN markets and a track record of licensing and commercialization deals, there is potential to target regional distributors, healthcare systems, and multinational pharma players expanding in Asia. Tailored market-entry programs, regulatory support, and co-marketing packages could accelerate adoption of AffaMed’s therapies and devices.